Septerna (NASDAQ:SEPN) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Septerna (NASDAQ:SEPN) released its quarterly earnings results on Monday. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.01), FiscalAI reports. The firm had revenue of $24.12 million for the quarter, compared to the consensus estimate of $20.44 million. Septerna had a negative return on equity of 15.78% and a negative net margin of 106.37%.

Septerna Stock Down 3.6%

SEPN opened at $28.02 on Wednesday. The firm has a market capitalization of $1.25 billion, a P/E ratio of -25.24 and a beta of 3.46. The stock has a fifty day moving average of $26.89 and a 200-day moving average of $23.25. Septerna has a 12-month low of $4.66 and a 12-month high of $32.63.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Raymond James Financial initiated coverage on shares of Septerna in a research note on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price objective on the stock. Wells Fargo & Company lifted their price target on Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a research report on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research note on Thursday, January 22nd. Wall Street Zen cut Septerna from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 10th. Finally, Zacks Research raised Septerna from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Septerna presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.83.

Insider Buying and Selling

In related news, COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total transaction of $115,880.00. Following the completion of the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $5,046,834.73. This trade represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Samira Shaikhly sold 70,453 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $28.10, for a total transaction of $1,979,729.30. Following the transaction, the insider owned 793 shares in the company, valued at approximately $22,283.30. This trade represents a 98.89% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.30% of the stock is owned by corporate insiders.

Institutional Trading of Septerna

A number of institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new position in shares of Septerna during the 4th quarter worth approximately $88,000. Seven Fleet Capital Management LP bought a new stake in Septerna during the fourth quarter worth about $319,000. XTX Topco Ltd acquired a new stake in shares of Septerna during the fourth quarter worth approximately $650,000. VARCOV Co. acquired a new stake in shares of Septerna during the fourth quarter worth approximately $631,000. Finally, Virtus Investment Advisers LLC bought a new position in shares of Septerna in the fourth quarter valued at approximately $292,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.